Angie’s most recent position was as CEO of Amunix Pharmaceuticals Inc., which Sanofi acquired for up to $1.225 billion. Angie previously was Chief Business & Strategy Officer and Head of Commercial for Sierra Oncology. During her tenure, she made an impact at the company with a successful initial public offer. She also led the business’s strategic and transactional endeavors, as well as producing a healthy pipeline through the purchase and acquisition of several product assets. At Aragon, she guided the company to its eventual acquisition by Johnson & Johnson. Angie also worked for Synosia Therapeutics and Ren Pharmaceuticals as their Chief Business Officer. She then concentrated on the new company formation at Venrock Ventures before joining Ren Pharmaceuticals. She also currently holds a position on the ORIC Pharmaceuticals board of directors.
Angie was awarded a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College.